Kenvue

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kenvue (KVUE) reports strong Q2 earnings, eyes China growth

Kenvue's Q2 performance showcased robust net sales, organic growth, and strategic investments in key segments. The company's focus on consumer trust, supply chain enhancements, and capital allocation strategy underpin its resilience. Challenges include managing inflationary pressures and sustaining growth post-COVID, but opportunities in China and ongoing investments position Kenvue for future success.

Kenvue (KVUE) reports solid Q3 performance amidst segment challenges

Kenvue (KVUE) delivered a solid Q3 performance, showcasing strength in key segments despite challenges in others.
The company's strategic initiatives, focus on innovation, and outlook for growth opportunities position it well for future success.
Efforts to address challenges in specific segments and capitalize on opportunities demonstrate a proactive approach to sustaining growth and profitability.
Overall positive outlook on third-quarter results reflects the company's strong model, portfolio, and cash flow generation capabilities.

Kenvue reports mixed 2023 performance, focuses on growth strategies

Kenvue's 2023 performance saw organic growth but faced challenges in specific segments, leading to adjustments for 2024. The company aims to drive growth through operational efficiencies, increased brand investments, and a focus on consumer engagement. Challenges in U.S. in-store execution prompted a recovery plan and leadership changes.

Kenvue surpasses Q1 expectations, eyes China growth amid challenges

Kenvue's Q1 performance exceeded expectations, driven by key segments and brands.
Strategic focus on cost optimization, operational efficiency, and brand impact.
Challenges include stabilizing declining segments and managing hyperinflation impact.
Opportunities lie in growing China business, operational reinvention, and new leadership.

Kenvue reports solid Q2 performance and optimistic outlook for 2024

Kenvue's Q2 performance reflects steady growth and improved profitability, driven by strategic initiatives and strong brand performance. While cost management and increased marketing spend pose challenges, the company's focus on brand investment and long-term value creation offers promising opportunities for future growth and shareholder returns.

Kenvue reports Q3 growth, tackles Skin Health challenges, eyes savings

Kenvue's Q3 performance showed organic growth and strong financial metrics.
While facing challenges in the Skin Health segment, the company is focusing on recovery.
Investments in marketing and efficiency improvements highlight growth opportunities.
Executives addressed key questions on guidance, inventory levels, and growth strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment focuses on oral care, baby care, women's health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

Brookfield Infrastructure Partners L.P.

Enterprise Products Partners

Brookfield Infrastructure's underlying businesses make its distributions highly dependable. Enterprise Products Partners has increased its distribution for 25 consecutive years and counting.

3 Super-Safe High-Yield Dividend Stocks You Can Buy Right Now

Sempra Energy

While many, if not most investors, appear bullish about the market's prospects this year, it's never a bad time to consider long-term dividend stocks. By that, we're talking about profitable, relevant enterprises that you can trust.

3 Unshakeable Dividend Stocks for Lifelong Wealth

Amazon

Duke Energy

Home Depot

Kroger

McDonald's

Microsoft

While avoiding a recession last year boosted sentiment for 2024, concerned investors may still want to consider stable stocks. You just don't know what might happen next.

7 Stable Stocks to Buy No Matter What Happens to Interest Rates

Agilent Technologies

Bristol-Myers

Core Laboratories Inc

Comcast

Compass Minerals

Campbell Soup

Corteva Inc

Disney

Estee Lauder

Emerson Electric

Etsy

Gilead Sciences

Huntington Ingalls Industries

Harley-Davidson

Honeywell

International Flavors & Fragrances

Altria

NIKE

Otis Worldwide

PepsiCo

Pfizer

Polaris

Ross Stores

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

U.S. Wide-Moat Stocks On Sale - The January 2024 Heat Map

Coinbase

Renaissance IPO ETF

Renaissance International IPO ETF

Smith Douglas Homes Corp

While the calendar was quiet this past week, six IPOs joined the pipeline, two of which we estimate could raise $1 billion or more. Three biotechs filed to raise $100 million.

U.S. IPO Weekly Recap: 2024 IPO Market Starts Off With $2B Additions To The Pipeline

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce financial results for the fourth quarter and full year ending December 31, 2023, on February 8, 2024.

Kenvue to Announce Fourth Quarter and Full Year 2023 Results on February 8, 2024

Costco

Lowe's

Ollie's Bargain Outlet Hlds

Procter & Gamble

One of the main themes of 2023 may be relief – that is, relief that we avoided a downcycle – and so it begs the question: why talk about 2024 recession worries? More to the point, why deal with recession stocks?

Still Worried About a 2024 Recession? 7 Stocks to Watch.

AbbVie

Archer-Daniels-Midland Company

Black Hills

Cincinnati Financial

Federal Realty Investment Trust

Fortis

Genuine Parts

Hormel Foods

Johnson & Johnson

Lancaster Colony

Leggett & Platt

National Fuel Gas

Northwest Natural Gas

United Bankshares

Universal Corp

"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of the Dow. The 54 Dividend Kings screened as of December 29 represented 9 of 11 Morningstar Sectors. Broker targeted-top-ten net-gains ranged 18.52%-38.49% topped-by Northwest Natural, and Altria Group. By yield, Altria tops-all. Top-ten Kingly January yields reported for ABBV, FTS, FRT, BKH, UVV, NWN, MMM, CDUAF, LEG, & MO averaged 5.45%.

January's 54 Dividend Kings: Buy 8, Watch 5

Clearway Energy

Vici Properties

Clearway Energy has the power to deliver high-end dividend growth in 2024. Kenvue should deliver the first of many dividend increases in the coming year.

3 Top Dividend Stocks I Can't Wait to Buy in 2024

ABM Industries

Clorox

Lam Research

NextEra Energy

York Water

Zoetis

Some investments just look after themselves. They are “set it and forget it” kind of stocks.

Forever Favorites: 7 Dividend Stocks to Buy and Never Sell

Dec 19 (Reuters) - A judge has barred expert witnesses from testifying that Johnson & Johnson (JNJ.N) spin-off Kenvue's (KVUE.N) painkiller Tylenol can cause autism if mothers take it during pregnancy, finding that they failed to support their conclusions with scientific evidence.

Lawsuits claiming Tylenol causes autism lack scientific support, judge finds

A ruling hurts litigation against Kenvue that alleges a link between prenatal exposure to the company's Tylenol and autism spectrum disorder or ADHD.

Kenvue Shares Are Rising. Tylenol Litigation Fades Into the Rearview.

B2Gold

Chevron

Casella Waste Systems

Silicom

With another year in the global markets coming to a close, now is a great time to consider stocks to buy for 2024. Part of the reason is to establish a framework for navigating the myriad uncertainties that could lie ahead.

7 New Year's Stocks to Buy to Get 2024 Off to a Bright Start

Shares of Tylenol maker Kenvue Inc. KVUE, +0.10% gained more than 5% premarket on Tuesday after a federal court judge in New York ruled that plaintiffs' expert testimony will be blocked in a case involving product-liability claims against the manufacturers of Tylenol and generic acetaminophen. Judge Denise Cote of U.S. District Court for the Southern District of New York on Monday granted the defendants' motion to exclude plaintiffs' expert opinions on whether in-utero exposure to acetaminophen could cause children to develop autism spectrum disorder and attention deficit hyperactivity disorder.

Kenvue shares rise after favorable court ruling in Tylenol litigation

Alphabet

Nippon Steel Corp

United States Steel

Naval taskforce formed to protect commercial vessels in the Red Sea from Houthi rebel attacks.

Naval Task Force; Japanese Takeover

Brookfield Renewable Partners

Kinder Morgan

STAG Industrial

Brookfield Renewable, Stag Industrial, Kinder Morgan, and Kenvue all pay high-yielding dividends. The companies should be able to increase their dividends in 2024 and beyond.

Got $4,000? These 4 Dividend Stocks Could Turn It Into Nearly $200 of Annual Income in 2024.

In May, Kenvue Inc. (KVUE, Financial) successfully concluded its separation from Johnson & Johnson (JNJ, Financial); however, its stock has experienced a decline about 25% since the completion of this process, likely driven by Investors nervousness about Tylenol litigation. The drop in value appears to be excessive even if the company may have to settle some lawsuits.

Kenvue: A High-Quality Consumer Health Company on Sale

Visa

Exxon Mobil

The last four years on Wall Street gave investors whiplash. A decade-long bull market came to a screeching halt as the global pandemic brought on one of the worst market crashes in recent memory.

Life-Changing Investments: 3 Stocks That Will Set You Up for the Long Haul

Verizon

AbbVie is proving its resilience with how it's navigating the loss of patent exclusivity for Humira. Kenvue markets iconic brands that should continue dominating the market for years to come.

3 Dividend Stocks You Can Safely Hold for Decades

LOS ANGELES, CA / ACCESSWIRE / December 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kenvue Inc. ("Kenvue" or "the Company") (NYSE:KVUE) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's May 2023 initial public offering ("IPO"), are encouraged to contact the firm before December 8, 2023.

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Kenvue Inc. with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kenvue Inc. (NYSE: KVUE) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company's May 2023 initial public offering (“IPO” or the “Offering”), of the important December 8, 2023 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purch.

KVUE DEADLINE TOMORROW: ROSEN, THE FIRST FILING FIRM, Encourages Kenvue Inc. Investors to Secure Counsel Before Important December 8 Deadline in Securities Class Action Commenced by the Firm – KVUE

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 8, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with the Company's May 2023 initial public offering (the “IPO” or “Offeri.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

RADNOR, Pa. , Dec. 7, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kenvue Inc. ("Kenvue") (NYSE: KVUE).

FINAL DEADLINE REMINDER FOR KVUE INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against Kenvue Inc. (KVUE)

BENSALEM, Pa. , Dec. 6, 2023 /PRNewswire/ -- Law Offices of Howard G.

KVUE Investors Have Opportunity to Lead Kenvue Inc. Securities Fraud Lawsuit

LOS ANGELES, CA / ACCESSWIRE / December 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kenvue Inc. ("Kenvue" or "the Company") (NYSE:KVUE) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's May 2023 initial public offering ("IPO"), are encouraged to contact the firm before December 8, 2023.

DECEMBER 8 DEADLINE: The Schall Law Firm Encourages Investors in Kenvue Inc. with Losses to Contact the Firm

News for Kenvue Stock (KVUE)